Opposite results were obtained in a retrospective analysis by Tongela et al. [35] on 128 women with stage I HER2+ breast cancers, in which there were no significant differences in relapse free survival and OS for the women with tumors <1 cm treated with Trastuzumab. Here, ERBB2 is linked to breast carcinoma.